TY - JOUR
T1 - Zika virus vaccine development
T2 - Progress in the face of new challenges
AU - Diamond, Michael S.
AU - Ledgerwood, Julie E.
AU - Pierson, Theodore C.
N1 - Funding Information:
This work was supported by grants from the National Institutes of Health (NIH) (R01 AI073755, R01 AI104972, U19 AI083019, and R01 HD091218) and by the Division of Intramural Research, National Institute of Allergy and Infectious Diseases, NIH. We thank Kimberly Dowd for helpful discussions and editorial comments on the manuscript. The authors apologize to colleagues for publications not cited due to space constraints imposed by the journal.
Publisher Copyright:
© 2019 by Annual Reviews.
PY - 2019/1/27
Y1 - 2019/1/27
N2 - Zika virus (ZIKV) emerged at a global level when it spread to the Americas and began causing congenital malformations and microcephaly in 2015. A rapid response by academia, government, public health infrastructure, and industry has enabled the expedited development and testing of a suite of vaccine platforms aiming to control and eliminate ZIKV-induced disease. Analysis of key immunization and pathogenesis studies in multiple animal models, including during pregnancy, has begun to define immune correlates of protection. Nonetheless, the deployment of ZIKV vaccines, along with the confirmation of their safety and efficacy, still has major challenges, one of which is related to the waning of the epidemic. In this review, we discuss the measures that enabled rapid progress and highlight the path forward for successful deployment of ZIKV vaccines.
AB - Zika virus (ZIKV) emerged at a global level when it spread to the Americas and began causing congenital malformations and microcephaly in 2015. A rapid response by academia, government, public health infrastructure, and industry has enabled the expedited development and testing of a suite of vaccine platforms aiming to control and eliminate ZIKV-induced disease. Analysis of key immunization and pathogenesis studies in multiple animal models, including during pregnancy, has begun to define immune correlates of protection. Nonetheless, the deployment of ZIKV vaccines, along with the confirmation of their safety and efficacy, still has major challenges, one of which is related to the waning of the epidemic. In this review, we discuss the measures that enabled rapid progress and highlight the path forward for successful deployment of ZIKV vaccines.
KW - ZIKV
KW - Zika virus
KW - antibody
KW - antibody-dependent enhancement
KW - dengue virus
KW - flavivirus
KW - neutralization
KW - vaccine
UR - http://www.scopus.com/inward/record.url?scp=85060575658&partnerID=8YFLogxK
U2 - 10.1146/annurev-med-040717-051127
DO - 10.1146/annurev-med-040717-051127
M3 - Review article
C2 - 30388054
AN - SCOPUS:85060575658
SN - 0066-4219
VL - 70
SP - 121
EP - 135
JO - Annual Review of Medicine
JF - Annual Review of Medicine
ER -